health
FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
In February, a Trump official refused to review the vaccine.
TL;DR
- FDA advisors voted 9-0 to approve Moderna's mRNA flu vaccine, mFlusiva.
- The vaccine showed 27% higher effectiveness against seasonal flu than standard shots in adults 50 and older.
- It also produced stronger immune responses than high-dose flu vaccines in individuals 65 and older.
- A Trump appointee initially blocked the vaccine's review, but the FDA reversed this decision.
- The FDA's final decision on approval is expected by August 5.
- A legal challenge has temporarily halted recommendations from the CDC's advisory committee, potentially impacting vaccine coverage.